Abstract
A novel bivalent albumin binder composed of two molecules of Lys-4-( p -iodophenyl)butyric acid markedly enhanced tumor retention of a FAP-targeted radioligand, suggesting its promising potential as a versatile pharmacokinetic modifier of radioligands.
Funding Information
  • Japan Agency for Medical Research and Development (JP24ama221604)
  • Japan Agency for Medical Research and Development (JP25ama221604)

This publication has 31 references indexed in Scilit: